News Express: International experts gather at UM to discuss TNFR2 immunoregulation and innovative drug development

新聞快訊:國際權威專家匯聚澳大 探討TNFR2免疫調節及創新藥物研製

 

宋永華
Yonghua Song

 


國際權威專家匯聚澳大 探討TNFR2免疫調節及創新藥物研製

“TNFR2免疫生物學及免疫藥理學國際研討會”於3月3日至4日在澳門大學舉行,吸引來自世界各地知名高等院校如哈佛大學、牛津大學、耶魯大學、約翰霍普金斯大學等國際頂尖專家學者及醫藥產業界研發人員參與。為期兩天的研討會為澳門及內地從事生命科學的專家提供了寶貴的交流與合作平台,青年科研人員更能藉此機會與國際知名科學家進行深入互動。

研討會由澳門大學中華醫藥研究院院長、中藥質量研究國家重點實驗室主任陳新與哈佛大學教授Denise L. Faustman共同組織。澳大校長宋永華在開幕式致辭表示,澳大一直致力推進生物醫學前沿領域的研究與教育,同時著力促進國際間的學術合作。陳新表示,澳門在TNFR2方面的研究成就已經成為全球科技界在該領域共同努力的一個重要組成部分,彰顯了澳門對當代科學技術的貢獻;他亦感謝澳門特別行政區科學技術發展基金對澳門開展TNFR2領域研究給予的重要支持。

研討會匯聚哈佛大學、牛津大學、耶魯大學、約翰霍普金斯大學、萊頓大學、美國國家衛生研究院/國家癌症研究所、法國國家健康與醫學研究院、圖盧茲大學、維爾茨堡大學、皇家墨爾本理工大學、加州大學聖地亞哥分校、梅奧診所醫學與科學學院、格羅寧根大學、根特大學、南丹麥大學、佛羅里達大學、邁阿密大學、杜克-新加坡國立大學醫學院、馬來西亞理科大學、澳門大學以及香港、內地著名學術與科研機構的科研人員。來自BioNTech-雷薩諾有限責任公司、波士頓免疫技術與治療公司、高誠生物、先聲藥業、阿諾醫藥等國際醫藥產業界代表則報告了對靶向TNFR2創新藥物研發的最新進展。

研討會還展示了21份來自不同國家及地區的海報,為學術交流提供更多互動契機。另外,研討會被美國白細胞生物學學會認定為其官方支持活動,設立優秀青年研究獎,評選優秀海報,並為獲獎者提供一千美元獎金。評審委員會由法國國家健康與醫學研究院教授Benoit L. Salomon、維爾茨堡大學教授Harald Wajant及約翰霍普金斯大學助理教授Nathan Archer組成,經過嚴格評選,澳門大學博士生陳忠豪、王一茹與百奧賽圖(北京)醫藥科技股份有限公司研究員周小飛獲該項殊榮。

此外,還有近300名來自世界各地知名高等院校、科研機構、製藥企業、創新基金機構的學生、學者及專業代表參與研討會,針對TNFR2在自體免疫疾病及腫瘤治療中的應用潛力展開深入研討。Denise L. Faustman在閉幕式上指出,如今科學界越來越重視TNFR2作為靶點在腫瘤與自體免疫疾病治療中的重要潛力,圍繞其免疫生物學機制的深入研究,對推動創新藥物的研發有重要意義,是次研討會的交流和討論為未來的突破性進展奠定了良好基礎。

澳門特別行政區科學技術發展基金行政委員會委員葉桂林、教育及青年發展局高等教育廳廳長許嘉路等出席了開幕式。

欲瀏覽官網版可登入以下連結:
https://www.um.edu.mo/zh-hant/news-and-press-releases/press-release/detail/60474/


International experts gather at UM to discuss TNFR2 immunoregulation and innovative drug development

The International Symposium on TNFR2 Immunobiology and Immunopharmacology was held at the University of Macau (UM) from 3 to 4 March 2025. The event brought together renowned experts and scholars from prestigious institutions worldwide, including Harvard University, University of Oxford, Yale University, and Johns Hopkins University, as well as R&D professionals from the pharmaceutical industry. The two-day symposium provided a valuable platform for exchange and cooperation among experts in life sciences from Macao and mainland China, allowing young researchers to interact with internationally renowned scientists.

The symposium was co-organised by Professor Chen Xin, director of the Institute of Chinese Medical Sciences and director of the State Key Laboratory of Quality Research in Chinese Medicine at UM, and Professor Denise L. Faustman from Harvard University. In his opening remarks, UM Rector Yonghua Song highlighted UM’s commitment to advancing research and education on the frontline of biomedicine and promoting international academic cooperation. Chen noted that Macao’s research achievements in TNFR2 (tumour necrosis factor receptor type II) have become an important part of global efforts in the field, showcasing Macao’s contributions to contemporary science and technology. He also thanked the Science and Technology Development Fund of the Macao SAR for its significant support of conducting TNFR2 research in Macao.

The event brought together researchers from Harvard University, University of Oxford, Yale University, Johns Hopkins University, Leiden University, National Cancer Institute (NCI) of the US National Institutes of Health (NIH), French National Institute of Health and Medical Research (Inserm), University of Toulouse, University of Würzburg, Royal Melbourne Institute of Technology (RMIT University), University of California, San Diego, Mayo Clinic College of Medicine and Science, University of Groningen, Ghent University, University of Southern Denmark, University of Florida, University of Miami, Duke-National University of Singapore (NUS) Medical School, Universiti Sains Malaysia, University of Macau (UM), and renowned academic and research institutions from Hong Kong and mainland China. Representatives from pharmaceutical companies worldwide, including BioNTech-resano GmbH, Boston Immune Technologies and Therapeutics (BITT), HiFiBiO Therapeutics, Simcere Pharmaceutical Group, and Adlai Nortye, reported on the latest research on the development of innovative drugs targeting TNFR2.

The symposium also featured 21 poster presentations from different countries and regions, providing more opportunities for academic exchange. Moreover, the symposium was an event officially endorsed by the US-based Society for Leukocyte Biology (SLB), which presented the Poster Award with prize of USD 1,000 to outstanding young researchers. The selection committee comprised of Professor Benoit L. Salomon from the French National Institute of Health and Medical Research (Inserm), Professor Harald Wajant from the University of Würzburg, and Assistant Professor Nathan Archer from Johns Hopkins University. After a rigorous selection process, UM doctoral students Chen Zhonghao and Wang Yiru, along with Zhou Xiaofei, a researcher from Biocytogen Pharmaceuticals (Beijing) Co Ltd, received the awards.

Nearly 300 students, scholars, and professionals from renowned universities, research institutes, pharmaceutical companies, and innovation funding agencies worldwide also attended the symposium and engaged in in-depth discussions on the potential applications of TNFR2 in the treatment of autoimmune diseases and cancer. In her closing remarks, Faustman said that TNFR2 is now considered a promising target in the treatment of tumours and autoimmune diseases. In-depth research into its immunobiological mechanisms is crucial for driving innovative drug development. She added that exchanges and discussions at the symposium have laid a solid foundation for future breakthroughs.

Also present at the opening ceremony of the symposium were Ip Kuai Lam, member of the Administrative Committee of the Science and Technology Development Fund of the Macao SAR and Carlos Roberto Xavier, head of the Department of Higher Education of the Education and Youth Development Bureau of the Macao SAR Government.

To read the news on UM’s official website, please visit the following link:
https://www.um.edu.mo/news-and-press-releases/press-release/detail/60474/